PropertyValue
?:abstract
  • Artemisinin-based combination therapies (ACTs) have demonstrated in vitro inhibition of SARS-CoV-2. Artemisinins have also shown anti-inflammatory effects, including inhibition of interleukin-6 that plays a key role in the development of severe COVID-19. There is now sufficient evidence for ACTs, and in particular artesunate/pyronaridine, to support clinical studies for COVID-19 infections.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1016/j.pt.2020.10.003
?:journal
  • Trends_Parasitol
?:license
  • els-covid
?:pdf_json_files
  • document_parses/pdf_json/64107afea90588c73ba2931852e90eaf734d531f.json
?:pmcid
?:pmid
?:pmid
  • 33153922.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Elsevier; Medline; PMC
?:title
  • Repurposing antimalarials to tackle the COVID-19 pandemic
?:type
?:year
  • 2020-10-19

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/3ls0po4k>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/3ls0po4k>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all